Skip to main content
. 2019 Jul 8;7:170. doi: 10.1186/s40425-019-0661-6

Fig. 2.

Fig. 2

Representative CT images from a 79-year-old man with advanced Merkel cell carcinoma. He experienced progressive disease after receiving pembrolizumab (two left panels). He then received ipilimumab + nivolumab + radiotherapy to cervical adenopathy, to which he developed a partial response (RECIST v1.1) 17 weeks into combinatorial therapy (right panel). PR was ongoing at 8 months when the patient died from complications related to encephalopathy, likely immune-mediated (i.e., a toxicity related to immune checkpoint inhibitor therapy)